10% Off $75 Orders! Use Code SAVE10P Shop Now
One use per customer. Not available with Autoship. Expires 5/28/18.

Comparison of tenoxicam & bromazepan in the treatment of fibromyalgia (FM): a ramdomized, double-blind, placebo-controlled trial

1 Star2 Stars3 Stars4 Stars5 Stars (72 votes, average: 3.25 out of 5)
Loading...

Fibromyalgia is a painful syndrome of non-articular origin,
predominantly involving muscles, and the commonest cause of
chronic widespread musculoskeletal pain. The diversity of
therapeutic programs for patients with fibromyalgia reflects
both the lack of a known pathophysiology for this disorder
and the low efficacy of the current therapies. We studied the
efficacy of tenoxicam and bromazepan in the treatment of
patients with fibromyalgia. One hundred and sixty-four
patients from our Rheumatology Outpatient Clinic fulfilling
the American College of Rheumatology criteria for the
classification of fibromyalgia, with widespread pain at study
entry. Each of the 164 patients was randomly assigned to 1 of
4 treatment groups: double placebo (P), tenoxicam (20 mg) +
placebo (T), bromazepan (3 mg) + placebo (B)m or tenoxicam
(20 mg) + bromazepan 3 mg (TB). Patient global assessment of
disease, pain, sleep quality, morning stiffness, and number
of tender points were evaluated at baseline and 8 weeks
afterwards. At the end of the trial, 17%, 10%, 12%, and 29%
of the P, T, B, and TB patients, respectively, had clinical
improvement. A statistically significant difference was found
only between the T and TB groups. Our data indicate that
treatment with tenoxicam + bromazepan can be effective for
some patients with fibromyalgia, but the differences with the
placebo group were neither clinically nor statistically
significant.

Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J,
Fernandez-Rodriguez A, Hernanz-Mediano W, Gutierrez-Rubio A, de la
Iglesia-Salgado JL, Garcia-Lopez A

1 Star2 Stars3 Stars4 Stars5 Stars (72 votes, average: 3.25 out of 5)
Loading...



Leave a Reply